Purpose: To evaluate the impact of adjuvant intravesical bacillus Calmette-Guérin (BCG) treatment in patients with high-grade transitional cell carcinoma of bladder. Patients and Methods: A total of 207 consecutive patients who underwent transurethral resection for high-grade T1 transitional cell carcinoma of bladder at our institution between January 1, 2005 and December 31, 2012. Of those patients, 77 underwent early cystectomy without BCG instillation and were excluded from the analysis. The overall survival and cancer-specific mortality were compared in 2 different therapy options groups (group of patients who received adjuvant BCG instillation vs. the group of patients who did not receive BCG therapy). Overall mortality was estimated by the Kaplan-Meier method, univariate comparisons were made with the log rank test. The cumulative incidence of deaths from bladder cancer (BC) was determined by univariate and multivariate competing risk analysis. Cox proportional hazard models for competing risks were used to study the combined effects of the variables on BC-specific mortality. Results: The 5-year overall survival in patients with BCG instillation vs. patients who did not receive BCG therapy was 74 vs. 28% (p = 0.0016). In the univariate analysis, the adjuvant intravesical BCG treatment was associated with decreased cancer-specific mortality (p = 0.0062). In the multivariable analysis, the age and the BCG instillation were independent factors of overall survival (hazard ratio 0.26, 95% CI 0.15-0.46, p < 0.0001) and cancer-specific mortality (hazard ratio 0.29, 95% CI 0.12-0.71, p = 0.0067). Conclusion: Dispensing from adjuvant intravesical BCG treatment is associated with increased overall- and disease-specific mortality in patients with T1 high-grade transitional cell carcinoma of bladder. This observation confirms that adjuvant BCG instillation is a crucial part of treatment in this patient population.

Journal Section:
Editor's choice
Keywords:
Bladder cancer, Transurethral resection, High-grade T1 bladder cancer, Bacillus Calmette-Guerin, Mortality
1.
Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA, Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-442.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.06.028
2.
Babjuk M, Böhle A, Burger E, Compérat E, Kaasinen E, Palou J, Roupret M, van Rhijn BWG, Shariat S, Sylvester R, Zigeuner R: Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1 and CIS). http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer (accessed November 13, 2015).
3.
Mostafid AH, Palou Redorta J, Sylvester R, Witjes JA: Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin. Eur Urol 2015;67:359-360.
[PubMed]
https://doi.org/10.1016/j.eururo.2014.11.031
4.
Dal Moro F: BCG shortage in Europe. Prev Med 2013;57:146.
[PubMed]
https://doi.org/10.1016/j.ypmed.2013.04.019
5.
Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-256.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.04.038
6.
Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD: Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485-490.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2003.04655.x
7.
Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-95.
[PubMed]
https://doi.org/10.1097/00005392-200301000-00023
8.
Han RF, Pan JG: Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-1223.
[PubMed]
https://doi.org/10.1016/j.urology.2005.12.014
9.
Pan J, Liu M, Zhou X: Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis. Front Med 2014;8:241-249.
[PubMed]
https://doi.org/10.1007/s11684-014-0328-0
10.
Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970.
[PubMed]
https://doi.org/10.1097/00005392-200211000-00016
11.
Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM: Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-773.
[PubMed]
https://doi.org/10.1016/j.eururo.2009.12.024
12.
Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A: Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 2013;112:742-750.
[PubMed]
https://doi.org/10.1111/bju.12012
13.
Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R: Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int 2015, Epub ahead of print.
[PubMed]
https://doi.org/10.1159/000430501
14.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475; discussion 475-477.
[PubMed]
https://doi.org/10.1016/j.eururo.2005.12.031
15.
Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W: Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2011;109:1026-1030.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2011.10462.x
16.
Huang H, Jin J, Li X: Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG. Pak J Med Sci 2014;30:1432.
[PubMed]
https://doi.org/10.12669/pjms.306.6408
17.
Hofbauer SL, Shariat SF, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas WC, Klatte T: The Moreau strain of bacillus Calmette-Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage? Urol Int 2015, Epub ahead of print.
[PubMed]
https://doi.org/10.1159/000440701
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.